Taysha Gene Therapies, Inc. (TSHA) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $49.26M; Long-Term Debt, Maturity, Year ThreeUSD $11.97M; Long-Term Debt, Maturity, Year FourUSD $38.03M; Long-Term Debt, Maturity, Year FiveUSD (m).
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $48.96M; Long-Term Debt, Maturity, Year ThreeUSD $11.97M; Long-Term Debt, Maturity, Year FourUSD $38.03M; Long-Term Debt, Maturity, Year FiveUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $50.11M; Long-Term Debt, Maturity, Year ThreeUSD (m); Long-Term Debt, Maturity, Year FourUSD (m); Long-Term Debt, Maturity, Year FiveUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Long-Term Debt, Maturity, Year ThreeUSD (m); Long-Term Debt, Maturity, Year FourUSD $11.97M; Long-Term Debt, Maturity, Year FiveUSD $38.03M.
Taysha Gene Therapies, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount, Noncurrent USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Unamortized Discount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $49.26M | $11.97M | $38.03M | (m) | $50.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $48.96M | $11.97M | $38.03M | (m) | $50.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $50.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $11.97M | $38.03M | $50.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $50.85M | (m) | $11.97M | $38.03M | $50.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $41.05M | $18.71M | $21.29M | (m) | $40.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $42.45M | $18.71M | $21.29M | (m) | $40.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $43.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $18.71M | $21.29M | $40.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $42.97M | $18.71M | $21.29M | (m) | $40.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $37.84M | $18.71M | $21.29M | (m) | $40.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $40.51M | $18.71M | $21.29M | (m) | $40.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $40.51M | (m) | (m) | (m) | (m) | $3.00M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $18.71M | $21.29M | $40.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $38.55M | $13.33M | (m) | (m) | $40.00M | $3.00M | (m) | $6.67M | $20.00M | (m) | $1.45M |
| 2023-06-30 | $38.35M | $13.33M | (m) | (m) | $40.00M | $3.00M | $38.35M | $6.67M | $20.00M | (m) | $1.65M |
| 2023-03-31 | $38.16M | $13.33M | (m) | (m) | $40.00M | $3.00M | $38.16M | $6.67M | $20.00M | (m) | $1.84M |
| 2022-12-31 | $37.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.67M | $20.00M | $13.33M | $40.00M | $3.00M | $37.97M | (m) | (m) | 11.25% | $2.03M |
| 2022-09-30 | $37.77M | $20.00M | $13.33M | (m) | $40.00M | $3.00M | $37.77M | (m) | $6.67M | (m) | $2.23M |
| 2022-06-30 | $37.58M | $20.00M | $13.33M | (m) | $40.00M | $3.00M | $37.58M | (m) | $6.67M | (m) | $2.42M |
| 2022-03-31 | $37.39M | $20.00M | $13.33M | (m) | $40.00M | $3.00M | $37.39M | (m) | $6.67M | (m) | $2.61M |
| 2021-12-31 | $37.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $6.67M | $20.00M | $13.33M | $40.00M | $3.00M | $37.19M | (m) | (m) | (m) | $2.81M |
| 2021-09-30 | $27.81M | $5.00M | $15.00M | $10.00M | $30.00M | $2.30M | $27.81M | (m) | (m) | (m) | $2.19M |
| 2021-08-12 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 7.00% | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |